Genomatica Revenue and Competitors

Location

$386.6M

Total Funding

Estimated Revenue & Valuation

  • Genomatica's estimated annual revenue is currently $58.7M per year.(i)
  • Genomatica received $90.0M in venture funding in October 2018.
  • Genomatica's estimated revenue per employee is $225,750
  • Genomatica's total funding is $386.6M.

Employee Data

  • Genomatica has 260 Employees.(i)
  • Genomatica grew their employee count by -3% last year.

Genomatica's People

NameTitleEmail/Phone
1
SVP, Specialty ProductsReveal Email/Phone
2
VP Research/DevelopmentReveal Email/Phone
3
VP Strategic PartnershipsReveal Email/Phone
4
VP, Process Technology & EngineeringReveal Email/Phone
5
Head Government AffairsReveal Email/Phone
6
EVPReveal Email/Phone
7
VP People & CultureReveal Email/Phone
8
Head Global CommunicationsReveal Email/Phone
9
SVPReveal Email/Phone
10
VP, Intellectual PropertyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3.8M26-10%N/AN/A
#2
$6.4M38-12%N/AN/A
#3
$428.2M142641%$5.6MN/A
#4
$2.1M1713%N/AN/A
#5
$104.2M3977%N/AN/A
#6
$42.9M1903%N/AN/A
#7
$59.8M2597%N/AN/A
#8
$3.4M2310%N/AN/A
#9
$6.6M39-7%N/AN/A
#10
$5.9M35-36%N/AN/A
Add Company

What Is Genomatica?

Genomatica is a widely-recognized technology leader for the chemical industry. We develop manufacturing processes that enable our licensee partners to produce the world's most widely-used chemicals a better way, from alternative feedstocks, with better economics and greater sustainability than petroleum-based processes. Genomatica has delivered the industry's first commercial biobased process for a high-volume intermediate chemical. Our GENO BDO process has produced thousands of tons of BDO and been licensed by BASF and Novamont. Multiple large chemical firms have publicly validated quality or described commercialization plans, including Invista (for its well-known Lycra® spandex), DSM, Lanxess, Toray, and Far Eastern New Century. Our biotechnology platform and over 500 patents and applications enable us to develop processes for additional major chemicals. The next is for butadiene, with Versalis and Braskem as partners, and over $100 million in industry support. We have also announced our program for nylon intermediates, including HMD, caprolactam and adipic acid. We've been honored to receive extensive recognition for our innovation, commercialization track record, and potential for broad impact. Recent examples include the Kirkpatrick Award, for the most noteworthy chemical engineering technology commercialized in the world, and the 2015 World Economic Forum Technology Pioneer award. See current job openings at www.genomatica.com/about/careers.

keywords:Biotechnology,Cleantech,Energy,Food & Beverages,Healthcare,Pharmaceuticals,Solar Power,Wind Power

$386.6M

Total Funding

260

Number of Employees

$58.7M

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Genomatica News

2022-04-19 - Bio-Based Butadiene Market Share 2022-2030| Key Players ...

Genomatica & Versalis; LanzaTech & Invista; Global Bioenergies & Synthos; Biokemik(Biosyncaucho). Bio-Based Butadiene Market Breakdown by Type: One...

2022-04-17 - Bio-Bdo Market Size, Outlook And Forecast | LCY Chemical ...

LCY Chemical, Genomatica, Global Bio-Chem, Novamont SpA. This comprehensive Bio-Bdo Market report helps in determining the deficiencies and...

2022-04-17 - Bio-organic Acid Market Size, Scope And Outlook | BioAmber ...

BioAmber, Myriant, Genomatica, BASF, DSM Cargill, Novozymes, Natureworks LLC, Dow Chemicals, Metabolix. Market factors could use prospect information to...

2021-08-19 - Lululemon Leggings Could Soon Be Made With Plant-Based Bio-Nylon

4 Mins Read Lululemon’s iconic leggings might soon be made using plant-based bio-nylon instead of the synthetic version that it’s currently made from. Partnering with Genomatica, the biotech making renewable materials, Luluemon is going to create a new lower-impact nylon from plant-based materi ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$34.5M261-14%N/A
#2
$68.6M26110%N/A
#3
$300M2610%$72M
#4
$15M26112%N/A
#5
$41M2633%N/A

Genomatica Funding

DateAmountRoundLead InvestorsReference
2010-03-29$15.0MCTPG BiotechArticle
2000-03-02$45.0MUndisclosedVantagePoint Venture PartnersArticle
2011-03-02$45.0MUndisclosedVantagePoint Venture PartnersArticle
2012-08-03$41.5MUndisclosedArticle
2014-03-10$6.8MUndisclosedArticle
2018-10-04$90.0MUndisclosedCasdin CapitalArticle